Peralta J, Poderoso J J, Corazza C, Fernández M, Guerreiro R B, Wiemeyer J C
Hospital de Clínicas José de San Martín, University of Buenos Aires, Argentina.
Arzneimittelforschung. 1987 Aug;37(8):969-71.
Twenty-three patients with exacerbations of chronic bronchitis were divided in two groups in a randomized fashion receiving either amoxicillin 1500 mg/d (n = 13) or amoxicillin 1500 mg/d associated with the mucolytic drug ambroxol 90 mg/d (n = 10). The improvement in cough, expectoration difficulties and sputum purulence was statistically more evident and occurred earlier in the ambroxol + amoxicillin group than in the amoxicillin only group. Although amoxicillin plasma and sputum levels were similar in both groups, the differences in daily sputum volume, which was also statistically greater in patients receiving ambroxol, suggests that this drug favours the bronchial mucus clearance of the antibiotic which could be related to the more favourable clinical evolution. No changes were observed in lung function tests and blood gases.
23例慢性支气管炎急性加重患者被随机分为两组，分别接受每日1500毫克阿莫西林治疗（n = 13）或每日1500毫克阿莫西林联合90毫克黏液溶解剂氨溴索治疗（n = 10）。与仅接受阿莫西林治疗的组相比，氨溴索+阿莫西林组在咳嗽、咳痰困难和痰液脓性方面的改善在统计学上更明显且出现得更早。尽管两组的阿莫西林血浆和痰液水平相似，但接受氨溴索治疗的患者每日痰量差异在统计学上也更大，这表明该药物有利于抗生素的支气管黏液清除，这可能与更有利的临床进展有关。肺功能测试和血气分析未观察到变化。
